recMAGE-A3 + AS15 ASCI

BIOLOGICAL2 trials

Sponsors

Craig L Slingluff, Jr, European Association of Urology Research Foundation

Conditions

MelanomaUrinary Bladder Neoplasms

Early Phase 1

Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

CompletedNCT01425749

Craig L Slingluff, JrMelanoma

Start: 2011-06-30End: 2015-10-31Updated: 2016-04-04

Phase 2

Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy

TerminatedNCT01435356

European Association of Urology Research FoundationUrinary Bladder Neoplasms

Start: 2011-08-31End: 2017-04-07Updated: 2019-01-09

Related Papers

611 RNA-sequencing reveals a unique immune transcriptional landscape in the vaccine sites of patients with circulating T-cell responses to cancer immunization

Regular and Young Investigator Award Abstracts2020-11-01